 |
|
Shining light on pancreatic cancer
August 01, 2007Experimental techniques show promise in screening for one of the nation's deadliest diseases
Using novel light-scattering techniques, researchers have found the first evidence that early stage pancreatic cancer causes subtle changes in part of the small intestine. The easily monitored marker may ultimately allow early detection for a disease notorious for having few obvious symptoms, the primary reason pancreatic cancer killed more than 33,000 Americans last year.
The new detection techniques, developed with support from the National Science Foundation (NSF), produce an optic fingerprint from the altered tissue and then enhance the data for a clearer diagnosis.
The researchers scanned tissue samples from 19 people already diagnosed with pancreatic cancer and 32 without the disease. They properly distinguished patients with cancer at an accuracy approaching 100 percent. The clearest results came from patients in the earliest stages of the disease.
Pancreatic cancer is so deadly, in part, because early detection is so difficult. The pancreas can become dangerously inflamed if examined directly, so routine inspections for at-risk patients are usually not an option.
The results build upon prior studies with colon cancer and support the "field effect" hypothesis that suggests initial cancer stages, even pre-cancerous lesions, can cause minute, potentially detectable changes throughout an entire organ. If similar results are found in other organs, the effect could have broad impact in the timely treatment of breast cancer, lung cancer and others.
The team of engineers from Northwestern University in Evanston, Ill., and physicians from Evanston-Northwestern Healthcare (ENH), reported the findings in the Aug. 1, 2007, Clinical Cancer Research.
"This novel technology uses light to probe tissue architecture at submicron scale. We are excited about this technology because it enables sensing subtle changes in tissue that otherwise are undetectable by conventional microscopic examination," said Northwestern engineer Vadim Backman, an NSF CAREER awardee who led the development of the new technologies and is a co-author on the research.
By studying tissue extracted from an area adjacent to the pancreas, the researchers were able to screen all 51 patients with little risk of inflammation or other complications.
While clinical use is perhaps three to five years in the future, and ongoing studies are needed to confirm the results, the researchers hope the tests can eventually be done without the biopsy.
"We were so encouraged by the successes with colon cancer that we decided to drive the research in a new direction. With colon cancer, you have time, even years, to treat it successfully. Unfortunately, for pancreatic cancer it's not only critical to detect it early, or even before it becomes cacnerous, but in many cases it is really the only hope," said Leon Esterowitz, the NSF program officer who has been supporting this research.
Because the study uses tissue samples taken from each patient's duodenum, the uppermost section of the small intestine which can be accessed during endoscopies, doctors could potentially generate earlier diagnoses by examining low-risk patients as part of routine examinations.
The next stages of the pancreatic cancer research trials incorporate some examinations that are biopsy-free and use a shoebox-sized fiber-optic version of the new system, a device now being tested during colonoscopies.
"Besides improving on the technology, we need to determine whether other medical conditions including other cancer types or diseases of the pancreas such as chronic pancreatitis or acute pancreatitis can be distinguished with our technology from pancreatic cancer. It is also important for us to validate our prediction rule on a larger number of pancreatic cancer cases as well as different control groups." said co-author Randall Brand, a gastroenterologist from ENH and an expert on pancreatic cancer.
In trials that began before the pancreas research, the researchers saw encouraging results with colon cancer detection in a study of 500 patients. The new approach also predicted, with 100 percent accuracy, polyps in patients diagnosed with a simultaneous colonoscopy.
Because the experimental procedure only scans the outer few centimeters of the colon and does not require the uncomfortable cleansing process required for a colonoscopy, the researchers believe the approach will encourage more people to get screened before they develop symptoms of disease.
The portable system was not used in the pancreatic cancer studies because the probe needs to be modified for the different scope used in endoscopy, but the underlying technology behind all of the examinations is the same. Each patient was scanned using a combination of elastic light-scattering and low-coherence enhanced backscattering techniques developed by Backman and his colleagues over the last five years. The researchers developed the four-dimensional elastic light scattering fingerprinting (4D-ELF) and low-coherence enhanced backscattering spectroscopy (LEBS) systems with the support of seven NSF grants, including a CAREER award.
Whether in a laboratory or in the portable, fiber-optic system, a xenon lamp shines intense, white light through a series of lenses and filters onto the specimen. The light refracts through the outermost layer of tissues and scatters into a spectrograph, a device that separates a beam of white light into its component wavelengths and measures them. An image sensor captures the result for analysis by a computer.
The technological breakthrough is the ability to cause light to penetrate the cells most affected by cancer without hitting deeper unaffected cells and to scan cell structures on the scale of nanometers, smaller than a doctor can see with a microscope.
"Contemporary diagnostic medicine frequently relies on invasive procedures, such as endoscopy, to detect disease. In the fictional world of Star Trek, a doctor is able to make a diagnosis without ever interrogating an organ. Biophotonics shows that this approach may be closer to reality that one might expect," added Backman.
The nanoscale approach allows the researchers to differentiate cancerous or pre-cancerous tissue from normal tissue, even if the specimens look identical under a normal biopsy.
In both studies, the techniques worked regardless of age, tumor size, smoking history or tumor location, although the researchers hope to use the next trial phase to test individuals with serious pancreatic diseases that are not cancer to see if the changes are truly unique to cancer. Eventually, the researchers hope to expand their study to breast cancer, lung cancer and other variations of the disease.
While the new techniques must undergo further study before its effectiveness can be confirmed, the researchers have partnered with American BioOptics to fully develop the technology. In July, American BioOptics received an NSF Small Business Innovation Research grant to further develop the technology for colon cancer screening and ready the system for commercialization.
National Science Foundation
The researchers scanned tissue samples from 19 people already diagnosed with pancreatic cancer and 32 without the disease. They properly distinguished patients with cancer at an accuracy approaching 100 percent. The clearest results came from patients in the earliest stages of the disease.
Pancreatic cancer is so deadly, in part, because early detection is so difficult. The pancreas can become dangerously inflamed if examined directly, so routine inspections for at-risk patients are usually not an option.
The results build upon prior studies with colon cancer and support the "field effect" hypothesis that suggests initial cancer stages, even pre-cancerous lesions, can cause minute, potentially detectable changes throughout an entire organ. If similar results are found in other organs, the effect could have broad impact in the timely treatment of breast cancer, lung cancer and others.
The team of engineers from Northwestern University in Evanston, Ill., and physicians from Evanston-Northwestern Healthcare (ENH), reported the findings in the Aug. 1, 2007, Clinical Cancer Research.
"This novel technology uses light to probe tissue architecture at submicron scale. We are excited about this technology because it enables sensing subtle changes in tissue that otherwise are undetectable by conventional microscopic examination," said Northwestern engineer Vadim Backman, an NSF CAREER awardee who led the development of the new technologies and is a co-author on the research.
By studying tissue extracted from an area adjacent to the pancreas, the researchers were able to screen all 51 patients with little risk of inflammation or other complications.
While clinical use is perhaps three to five years in the future, and ongoing studies are needed to confirm the results, the researchers hope the tests can eventually be done without the biopsy.
"We were so encouraged by the successes with colon cancer that we decided to drive the research in a new direction. With colon cancer, you have time, even years, to treat it successfully. Unfortunately, for pancreatic cancer it's not only critical to detect it early, or even before it becomes cacnerous, but in many cases it is really the only hope," said Leon Esterowitz, the NSF program officer who has been supporting this research.
Because the study uses tissue samples taken from each patient's duodenum, the uppermost section of the small intestine which can be accessed during endoscopies, doctors could potentially generate earlier diagnoses by examining low-risk patients as part of routine examinations.
The next stages of the pancreatic cancer research trials incorporate some examinations that are biopsy-free and use a shoebox-sized fiber-optic version of the new system, a device now being tested during colonoscopies.
"Besides improving on the technology, we need to determine whether other medical conditions including other cancer types or diseases of the pancreas such as chronic pancreatitis or acute pancreatitis can be distinguished with our technology from pancreatic cancer. It is also important for us to validate our prediction rule on a larger number of pancreatic cancer cases as well as different control groups." said co-author Randall Brand, a gastroenterologist from ENH and an expert on pancreatic cancer.
In trials that began before the pancreas research, the researchers saw encouraging results with colon cancer detection in a study of 500 patients. The new approach also predicted, with 100 percent accuracy, polyps in patients diagnosed with a simultaneous colonoscopy.
Because the experimental procedure only scans the outer few centimeters of the colon and does not require the uncomfortable cleansing process required for a colonoscopy, the researchers believe the approach will encourage more people to get screened before they develop symptoms of disease.
The portable system was not used in the pancreatic cancer studies because the probe needs to be modified for the different scope used in endoscopy, but the underlying technology behind all of the examinations is the same. Each patient was scanned using a combination of elastic light-scattering and low-coherence enhanced backscattering techniques developed by Backman and his colleagues over the last five years. The researchers developed the four-dimensional elastic light scattering fingerprinting (4D-ELF) and low-coherence enhanced backscattering spectroscopy (LEBS) systems with the support of seven NSF grants, including a CAREER award.
Whether in a laboratory or in the portable, fiber-optic system, a xenon lamp shines intense, white light through a series of lenses and filters onto the specimen. The light refracts through the outermost layer of tissues and scatters into a spectrograph, a device that separates a beam of white light into its component wavelengths and measures them. An image sensor captures the result for analysis by a computer.
The technological breakthrough is the ability to cause light to penetrate the cells most affected by cancer without hitting deeper unaffected cells and to scan cell structures on the scale of nanometers, smaller than a doctor can see with a microscope.
"Contemporary diagnostic medicine frequently relies on invasive procedures, such as endoscopy, to detect disease. In the fictional world of Star Trek, a doctor is able to make a diagnosis without ever interrogating an organ. Biophotonics shows that this approach may be closer to reality that one might expect," added Backman.
The nanoscale approach allows the researchers to differentiate cancerous or pre-cancerous tissue from normal tissue, even if the specimens look identical under a normal biopsy.
In both studies, the techniques worked regardless of age, tumor size, smoking history or tumor location, although the researchers hope to use the next trial phase to test individuals with serious pancreatic diseases that are not cancer to see if the changes are truly unique to cancer. Eventually, the researchers hope to expand their study to breast cancer, lung cancer and other variations of the disease.
While the new techniques must undergo further study before its effectiveness can be confirmed, the researchers have partnered with American BioOptics to fully develop the technology. In July, American BioOptics received an NSF Small Business Innovation Research grant to further develop the technology for colon cancer screening and ready the system for commercialization.
National Science Foundation
Pancreatic Cancer Current Events and Pancreatic Cancer News RSS2 new compounds show promise for eliminating breast cancer tumors
Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors.
The miseries of allergies just may help prevent some cancers, study finds
There may be a silver -- and healthy -- lining to the miserable cloud of allergy symptoms: Sneezing, coughing, tearing and itching just may help prevent cancer -- particularly colon, skin, bladder, mouth, throat, uterus and cervix, lung and gastrointestinal tract cancer, according to a new Cornell study.
Cancer drugs my build and not tear down blood vessels
Scientists have thought that one way to foil a tumor from generating blood vessels to feed its growth - a process called angiogenesis - was by creating drugs aimed at stopping a key vessel growth-promoting protein. But now the opposite seems to be true.
UC Davis researchers discover Achilles' heel in pancreatic cancer
UC Davis Cancer Center researchers have discovered a metabolic deficiency in pancreatic cancer cells that can be used to slow the progress of the deadliest of all cancers.
Jefferson Department of Surgery announces new pancreas tumor registry
Charles J. Yeo, M.D., Samuel D. Gross Professor and Chair, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, announces the establishment of the new Jefferson Pancreas Tumor Registry (JPTR).
Supercomputer provides massive computational boost to biomedical research at TGen
In less time than the blink of an eye, the Translational Genomics Research Institute's new supercomputer at Arizona State University can do operations equal to every dollar in the recent Wall Street bailout.
Hepatitis B exposure may increase risk for pancreatic cancer
In a first-of-its-kind finding, researchers at The University of Texas M. D. Anderson Cancer Center have discovered that exposure to the hepatitis B virus (HBV) may increase the risk of pancreatic cancer.
Study finds association between hepatitis B and pancreatic cancer
A new study has shown that evidence of past hepatitis B infection was twice as common in people with pancreatic cancer than in healthy controls. This study is the first to report an association between past exposure to the hepatitis B virus and pancreatic cancer, but researchers cautioned that more studies are necessary to evaluate the nature of the link.
Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
A research team, led by investigators at the Department of Surgery at Jefferson Medical College of Thomas Jefferson University and the Kimmel Cancer Center at Jefferson, has achieved a substantial "kill" of pancreatic cancer cells by using nanoparticles to successfully deliver a deadly diphtheria toxin gene.
The effective chemoradiotherapy method for pancreatic cancer
Pancreatic cancer is the fifth most common cause of cancer death in Japan. The prognosis is extremely poor because it is difficult to detect this disease in the early stage and also the postoperative incidence of recurrence is still high, and we have not had any effective treatment for inoperable patients.
More Pancreatic Cancer Current Events and Pancreatic Cancer News Articles
 | 100 Q&A About Pancreatic Cancer (100 Questions Series) by Joanne Frankel Kelvin Eileen O'Reilly EMPOWER YOURSELF! Whether you’re a newly diagnosed pancreatic cancer patient, a survivor, or a friend or relative of someone with pancreatic cancer, this book offers help. The only text to provide a doctor’s and patient’s view, 100 Questions & Answers About Pancreatic Cancer gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of... |
 | Pancreatic Cancer (M.D. Anderson Solid Tumor Oncology Series) Since the previous M.D. Anderson Solid Tumor Oncology Series publication on pancreatic cancer, there have been major advances in our understanding of molecular events which underlie pancreatic cancer development, both in the sporadic and inherited forms. We have seen the development of the first mouse models that accurately recapitulate features of the human disease. Several landmark clinical... |
 | My Journey With Pancreatic Cancer by Calvin E. Rains Sr. This book is shared to help all understand the cancer affecting the pancreas which is a vital organ in the digestion of food. Pancreatic cancer is one of the most deadly of cancers affecting the human body. Less than 5% of those diagnosed with Pancreatic Cancer survive the first year. This book is intended to help the patient, their families, and friends to understand the dangers and possible... |
| 100 Questions & Answers About Pancreatic Cancer, 2nd Edition (100 Questions & Answers about . . .) by Eileen O'Reilly Empower yourself!Whether you're a newly diagnosed pancreatic cancer patient, a survivor, or friend or relative of someone with pancreatic cancer, this book offers help. The only text to provide a doctor's and a patient's view, 100 Questions & Answers About Pancreatic Cancer, Second Edition gives you authoritative, practical answers to your questions about treatment options, post-treatment quality... | |
| Pancreatic Cancer (American Cancer Society Atlas of Clinical Oncology) by John L. Cameron At present, there are approximately 28,300 new cases of pancreatic cancer in the United States. It is the fourth leading cause of cancer death in men and women. Approximately 2 out of 10 patients with cancer of the pancreas will live at least one year after the cancer is found, but only a very few will survive for five or more years. The editors have brought together a stellar team of... | |
 | Pancreatic Cancer by Daniel D. Von Hoff (Editor) Praise for the book “An outstanding text covering all aspects of pancreatic cancer, from embryology through genetics and pathology, and including all avenues of treatment. There are 112 internationally recognized authors, the book is marvelously illustrated, and is a must for all scientists and clinicians interested in neoplasms of the pancreas. It is currently the most up-to-date and... |
 | The Official Patient's Sourcebook on Pancreatic Cancer: A Revised and Updated Directory for the Internet Age by Icon Health Publications This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to pancreatic cancer (also Cancer pancreas; Pancreatic cancer), from the... |
 | Pancreatic Cancer (Recent Results in Cancer Research) Although pancreatic cancer is one of the most serious forms of cancers, the outlook for patients could be improved. The lack of clinical symptoms of early, surgically removable disease most often limits curative treatment options. The aggressive tumor cell biology, leading to a locally advanced nature of the disease and to early metastases, allows curative resection in only 20% of patients at the... |
 | Myths & Facts About Pancreatic Cancer; What You Need to Know Facts about pancreatic... |
 | Pancreatic Cancer: Methods and Protocols (Methods in Molecular Medicine) (Methods in Molecular Medicine) This ambitious collection of essential yet novel methods for pancreatic cancer research or cancer research in general features an outstanding cast of authors who are esteemed leaders in the field. The authors provide a broad range of methods for molecular, biochemical, pathological, and statistical analysis of sporadic and familial pancreatic cancer, methods that can be applied not only to basic,... |
| © 2008 BrightSurf.com |